KBYPF (Kobayashi Pharmaceutical Co) Cyclically Adjusted PS Ratio: (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KBYPF Kobayashi Pharmaceutical Co Ltd KBYPF
79 GF Score
Price $34.05
GF Value $29.30
! 6 Warning Signs
View Full Analysis

What is Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kobayashi Pharmaceutical Co  (OTCPK:KBYPF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Kobayashi Pharmaceutical Co Annual Data
Trend Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.89 4.57 3.25 2.81 2.36

Kobayashi Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.40 2.37 2.36 2.58 0.00

KBYPF vs PG, CL, EL: Cyclically Adjusted PS Ratio Comparison

For the Household & Personal Products subindustry, Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


KBYPF
79GF Score
Kobayashi Pharmaceutical Co Ltd KBYPF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Kobayashi Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/113.6000*113.6000
=0.000

Current CPI (Jun. 2026) = 113.6000.

Kobayashi Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.601 98.000 5.333
201612 4.919 98.400 5.679
201703 3.453 98.100 3.999
201706 4.187 98.500 4.829
201709 4.610 98.800 5.301
201712 5.501 99.400 6.287
201803 4.022 99.200 4.606
201806 4.477 99.200 5.127
201809 4.861 99.900 5.528
201812 5.828 99.700 6.641
201903 3.610 99.700 4.113
201906 4.444 99.800 5.059
201909 4.981 100.100 5.653
201912 5.528 100.500 6.249
202003 3.792 100.300 4.295
202006 4.075 99.900 4.634
202009 4.710 99.900 5.356
202012 5.604 99.300 6.411
202103 3.563 99.900 4.052
202106 4.274 99.500 4.880
202109 4.716 100.100 5.352
202112 5.360 100.100 6.083
202203 3.556 101.100 3.996
202206 3.730 101.800 4.162
202209 3.885 103.100 4.281
202212 5.035 104.100 5.494
202303 3.292 104.400 3.582
202306 3.732 105.200 4.030
202309 4.042 106.200 4.324
202312 5.028 106.800 5.348
202403 3.276 107.200 3.472
202406 3.123 108.200 3.279
202409 3.888 108.900 4.056
202412 4.470 110.700 4.587
202503 2.945 111.100 3.011
202506 3.390 111.700 3.448
202509 3.914 112.000 3.970
202512 4.633 113.000 4.658
202603 2.857 112.700 2.880
202606 0.000 113.600 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Kobayashi Pharmaceutical Co (KBYPF) Overvalued in 2026?

Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co stock appears to be overvalued. The current stock price of $34.05 is trading 16.2% above its estimated GF Value™ of $29.30.

Key valuation signals for KBYPF:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $29.30 vs. price of $34.05 (16.2% above fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the KBYPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kobayashi Pharmaceutical Co Business Description

Other Exchanges 4967:Japan
Address 4-4-10 Doshomachi, KDX Kobayashi Doshomachi Building, Chuo-ku, Osaka, JPN, 541-0045
Kobayashi Pharmaceutical Co Ltd is engaged in the manufacture and sale of healthcare products, daily necessities, and body warmers. The company operates through two reportable segments: Domestic Business and International Business, which handle production and sales activities in Japan and overseas, respectively. The company's product portfolio includes disposable body warmers, cooling gel sheets, OTC pharmaceuticals, oral hygiene products, air fresheners, eyeglass wipes, and deodorizing/household sundries.
79GF Score

Get the complete analysis for KBYPF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.05
Price
$29.30
GF Value